Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 1 (January)

1. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
   Mod Pathol, 18(1): 19-25. [Abstract] [Full-text]
2. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis.
   J Natl Cancer Inst, 97(1): 51-9. [Abstract] [Full-text]
3. Vascular leukocytes contribute to tumor vascularization.
   Blood, 105(2): 679-81. [Abstract] [Full-text]
4. Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma.
   Biochem J, 385: 595-603. [Abstract] [Full-text]
5. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
   Nat Med, 11(1): 63-70. [Abstract] [Full-text]
6. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy.
   Gene Ther, 12(2): 187-93. [Abstract] [Full-text]
7. Screening and detection of ovarian cancer.
   J Midwifery Womens Health, 50(1): 51-4. [Abstract] [Full-text]
8. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
   Eur J Surg Oncol, 31(1): 67-73. [Abstract] [Full-text]
9. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells.
   J Clin Endocrinol Metab, 90(1): 207-10. [Abstract] [Full-text]
10. Atypical papillary proliferation in gynecologic patients: a study of 32 pelvic washes.
    Diagn Cytopathol, 32(2): 76-81. [Abstract] [Full-text]
11. Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene.
    Cancer Sci, 96(1): 26-30. [Abstract] [Full-text]
12. Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells.
    Endocrinology, 146(2): 760-8. [Abstract] [Full-text]
13. CYP1A1 alleles in female genital cancers in the Polish population.
    Eur J Obstet Gynecol Reprod Biol, 118(2): 246-50. [Abstract] [Full-text]
14. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Biochem Pharmacol, 69(3): 373-83. [Abstract] [Full-text]
15. Why institutions do not participate in ovarian cancer trials -- results from a survey in Germany.
    Onkologie, 28(1): 13-7. [Abstract] [Full-text]
16. Up-regulated expression of cytoplasmic clusterin in human ovarian carcinoma.
    Cancer, 103(2): 277-83. [Abstract] [Full-text]
17. High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas.
    Genes Chromosomes Cancer, 42(3): 228-37. [Abstract] [Full-text]
18. Oophorectomy during surgery for colorectal carcinoma.
    Tech Coloproctol, 8: s214-6. [Abstract] [Full-text]
19. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line.
    Ann N Y Acad Sci, 1030: 162-9. [Abstract] [Full-text]
20. Role of the hedgehog/patched signaling pathway in oncogenesis: a new polymorphism in the PTCH gene in ovarian fibroma.
    Ann N Y Acad Sci, 1030: 134-43. [Abstract] [Full-text]
21. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
    Eur J Cancer, 41(2): 323-33. [Abstract] [Full-text]
22. Metastases of breast carcinoma to the uterus. Report of two cases, one harboring a primary endometrioid carcinoma, with review of the literature.
    Gynecol Oncol, 96(2): 543-7. [Abstract] [Full-text]
23. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers.
    Gynecol Oncol, 96(2): 531-8. [Abstract] [Full-text]
24. Histologic types of epithelial ovarian cancer: have they different risk factors?
    Gynecol Oncol, 96(2): 520-30. [Abstract] [Full-text]
25. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis.
    Gynecol Oncol, 96(2): 516-9. [Abstract] [Full-text]
26. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis.
    Gynecol Oncol, 96(2): 462-9. [Abstract] [Full-text]
27. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    Gynecol Oncol, 96(2): 444-51. [Abstract] [Full-text]
28. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
    Gynecol Oncol, 96(2): 439-43. [Abstract] [Full-text]
29. Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells.
    Gynecol Oncol, 96(2): 430-8. [Abstract] [Full-text]
30. Benign ovarian serous tumors: a re-evaluation and proposed reclassification of serous "cystadenomas" and "cystadenofibromas".
    Gynecol Oncol, 96(2): 395-401. [Abstract] [Full-text]
31. Salvage whole-abdominal radiation therapy after second-look laparotomy or secondary debulking surgery in patients with ovarian cancer.
    Gynecol Oncol, 96(2): 389-94. [Abstract] [Full-text]
32. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
    Gynecol Oncol, 96(2): 374-80. [Abstract] [Full-text]
33. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Gynecol Oncol, 96(2): 355-61. [Abstract] [Full-text]
34. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma.
    Gynecol Oncol, 96(2): 330-4. [Abstract] [Full-text]
35. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Gynecol Oncol, 96(2): 323-9. [Abstract] [Full-text]
36. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
    Gynecol Oncol, 96(2): 307-13. [Abstract] [Full-text]
37. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer.
    Gynecol Oncol, 96(2): 301-6. [Abstract] [Full-text]
38. A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
    Gynecol Oncol, 96(2): 296-300. [Abstract] [Full-text]
39. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Gynecol Oncol, 96(2): 287-95. [Abstract] [Full-text]
40. Chewing pattern in patients with Meige's syndrome.
    Mov Disord, 20(1): 26-33. [Abstract] [Full-text]
41. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Hum Pathol, 35(11): 1360-8. [Abstract] [Full-text]
42. A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA1 and BRCA2 mutations.
    Ann Oncol, 16(2): 322-9. [Abstract] [Full-text]
43. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma.
    Ann Oncol, 16(2): 300-6. [Abstract] [Full-text]
44. A case of protrusion of an intraperitoneal chemotherapy catheter through rectum.
    Int J Gynecol Cancer, 15(1): 171-4. [Abstract] [Full-text]
45. Microvessel quantification in benign and malignant ovarian tumors.
    Int J Gynecol Cancer, 15(1): 58-65. [Abstract] [Full-text]
46. Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays.
    Int J Gynecol Cancer, 15(1): 50-7. [Abstract] [Full-text]
47. Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy.
    Int J Gynecol Cancer, 15(1): 45-9. [Abstract] [Full-text]
48. Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546.
    Int J Gynecol Cancer, 15(1): 37-44. [Abstract] [Full-text]
49. Clinical features of hepatic metastasis in patients with ovarian cancer.
    Int J Gynecol Cancer, 15(1): 26-31. [Abstract] [Full-text]
50. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients.
    Int J Gynecol Cancer, 15(1): 19-25. [Abstract] [Full-text]
51. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
    Int J Cancer, 114(2): 224-9. [Abstract] [Full-text]
52. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase.
    Int J Cancer, 114(1): 19-31. [Abstract] [Full-text]
53. Myometrial invasion and cervical invasion by endometrial carcinoma: evaluation by CO2-volumetric interpolated breathhold examination (VIBE).
    J Magn Reson Imaging, 21(2): 166-71. [Abstract] [Full-text]
54. Splenectomy for solitary splenic metastasis of ovarian cancer.
    BMC Cancer, 4(1): 96. [Abstract] [Full-text]
55. Ovarian fibroma in a 7-month-old infant: a case report and review of the literature.
    Pediatr Surg Int, 20(11): 894-7. [Abstract] [Full-text]
56. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
    Jpn J Clin Oncol, 35(1): 23-7. [Abstract] [Full-text]
57. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    J Clin Oncol, 23(4): 751-8. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.